Drugs / anti-BCMA:TCRζ-4-1-BB CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03093168 | Feb 2017 → Sep 2019 | plasma cell myeloma | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-BCMA:TCRζ-4-1-BB CAR-T cells | “Administration of anti-BCMA:TCRζ-4-1-BB CAR-T cells to patients with multiple myeloma” NCT03093168 ↗ |
| Action | Deplete | “To investigate the tumor killing capability of BCMA CAR-T cells in vitro” NCT03093168 ↗ |
| Modality | Cell therapy | “Retroviral vector-transduced autologous T cells to express anti-BCMA CAR” NCT03093168 ↗ |